OCTAPHARMA

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1983-01-01

Employees: -

Market Cap: -

Website: https://www.octapharma.com/

Clinical Trials

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Not yet recruiting

Conditions: Significant Bleeding Risk
Vitamin K-Dependent Coagulation Defect

Interventions: Drug: Balfaxar
Drug: Kcentra

First Posted Date: 2024-05-28

Last Posted Date: 2024-05-28

Lead Sponsor: Octapharma

Target Recruit Count: 3574

Registration Number: NCT06429787

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Phase 3

Recruiting

Conditions: Acute Hereditary Angio Edema

Interventions: Drug: OCTA-C1-INH
Other: Placebo

First Posted Date: 2024-04-12

Last Posted Date: 2024-12-04

Lead Sponsor: Octapharma

Target Recruit Count: 124

Registration Number: NCT06361537

Locations: 🇺🇦
Octapharma Research Site, Lviv, Ukraine

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Phase 3

Recruiting

Conditions: Acquired Antithrombin Deficiency

Interventions: Drug: Human plasma derived antithrombin
Drug: Placebo

First Posted Date: 2023-10-23

Last Posted Date: 2024-11-22

Lead Sponsor: Octapharma

Target Recruit Count: 120

Registration Number: NCT06096116

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
🇺🇸
OU Health University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States

and more 2 locations

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Phase 4

Recruiting

Conditions: Hemophilia A

Interventions: Drug: Nuwiq

First Posted Date: 2023-07-10

Last Posted Date: 2024-10-23

Lead Sponsor: Octapharma

Target Recruit Count: 28

Registration Number: NCT05936580

Locations: 🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
🇩🇪
Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany
🇬🇧
St. James's University Hospital, Leeds, United Kingdom

and more 10 locations

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Phase 4

Recruiting

Conditions: Severe Hemophilia A

Interventions: Drug: Nuwiq

First Posted Date: 2023-07-07

Last Posted Date: 2024-10-28

Lead Sponsor: Octapharma

Target Recruit Count: 28

Registration Number: NCT05935358

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇫🇷
CHRU de Tours, Tours, France

and more 14 locations

Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

Phase 3

Completed

Conditions: Bleeding Cardiac Surgery Patients

Interventions: Drug: Octaplex
Drug: Frozen Plasma Product, Human

First Posted Date: 2022-08-31

Last Posted Date: 2024-07-25

Lead Sponsor: Octapharma

Target Recruit Count: 419

Registration Number: NCT05523297

Locations: 🇺🇸
Duke University Health System, Durham, North Carolina, United States
🇨🇦
University of British Columbia and Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada
🇨🇦
Sunnybrook Hospital, Toronto, Ontario, Canada

and more 10 locations

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age

Phase 3

Completed

Conditions: Von Willebrand Disease

Interventions: Drug: wilate

First Posted Date: 2021-07-08

Last Posted Date: 2024-12-18

Lead Sponsor: Octapharma

Target Recruit Count: 12

Registration Number: NCT04953884

Locations: 🇲🇰
PHI University Clinic for Child Diseases, Skopje, North Macedonia
🇷🇺
FSBI National Research Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
🇺🇦
Danylo Halytsky Lviv National Medical University, Communal Institution of Lviv Regional Council "Western Ukrainian Specialized Children's Medical Centre", Lviv, Ukraine

and more 6 locations

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Phase 3

Recruiting

Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy

Interventions: Drug: Panzyga

First Posted Date: 2021-06-18

Last Posted Date: 2024-11-18

Lead Sponsor: Octapharma

Target Recruit Count: 30

Registration Number: NCT04929236

Locations: 🇺🇸
Octapharma Research Site, Philadelphia, Pennsylvania, United States

Efficacy of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Phase 3

Recruiting

Conditions: Congenital Antithrombin Deficiency

Interventions: Drug: Atenativ

First Posted Date: 2021-06-08

Last Posted Date: 2024-11-04

Lead Sponsor: Octapharma

Target Recruit Count: 38

Registration Number: NCT04918173

Locations: 🇩🇪
UKB Bonn Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn, Germany
🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 20 locations

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

Phase 3

Recruiting

Conditions: Acute Major Bleeding

Interventions: Drug: Octaplex

First Posted Date: 2021-04-30

Last Posted Date: 2024-12-13

Lead Sponsor: Octapharma

Target Recruit Count: 260

Registration Number: NCT04867837

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇹🇷
SBU Adana City Education and Research Hospital, Adana, Turkey
🇹🇷
Mersin University Faculty of Medicine, Mersin, Turkey

and more 55 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy